Sanjiv Patel - Jun 30, 2024 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President and CEO, Director
Signature
/s/ Thomas Catinazzo, as Attorney-in-Fact
Stock symbol
RLAY
Transactions as of
Jun 30, 2024
Transactions value $
$11,678
Form type
4
Date filed
7/1/2024, 04:43 PM
Previous filing
Jan 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Award $11.7 K +2.11 K +0.28% $5.54 766 K Jun 30, 2024 Direct F1, F2, F3
holding RLAY Common Stock 675 K Jun 30, 2024 By The Patel Family Irrevocable Trust of 2019 F4
holding RLAY Common Stock 687 K Jun 30, 2024 By The SSP Irrevocable Trust of 2020 F4

Explanation of Responses:

Id Content
F1 The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
F2 In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 28, 2024.
F3 Includes 762,360 shares underlying restricted stock units.
F4 These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.